 Lucira Health Inc NASDAQ: LHDX reported sales of 12.4 million in Q2, the firms second full quarter of commercial activity, beating the consensus estimate of 8 million. Sales increased 175 sequentially, propelled by the volume of Lucira Check It COVID-19 Test Kit sales through the OTC indication, increased customer contracts, and international demand. 